Neuroinflammation in Parkinson's disease: Role in neurodegeneration and tissue repair

International Journal of Neuroscience

Volumn 125, Issue 10, 2015, Pages 717-725

  Vivekanantham, Sayinthen ^a   Shah, Savan ^a   Dewji, Rizwan ^a   Dewji, Abbas ^a   Khatri, Chetan ^a   Ologunde, Rele ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Ageing; Alpha synuclein; Dopamine; Inflammation; Microglia; Neuroinflammation; Nigrostriatal; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; NUCLEAR RECEPTOR RELATED FACTOR 1; PARKIN; ANTIINFLAMMATORY AGENT;

CELL ACTIVATION; CELL FUNCTION; CELL SURVIVAL; GENETIC SUSCEPTIBILITY; HUMAN; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PHENOTYPE; REVIEW; TISSUE REPAIR; ANIMAL; BRAIN; COMPLICATION; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; DOPAMINERGIC NEURONS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; MICROGLIA; NERVE DEGENERATION; PARKINSON DISEASE;

EID: 84940566058     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2014.982795     Document Type: Review

References (86)

1. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008; 23 (4): 474-83.
2. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Ann Rev Neurosci 2005; 28: 57-87.
3. Mizuno Y, Hattori N, Kitada T, et al. Familial Parkinson's disease. Alpha-synuclein and parkin. Adv Neurol 2001; 86: 13-21.
4. Tanner CM. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol 2003; 91: 133-42.
5. Nagatsu T, Sawada M. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol 2006; 26 (4-6): 781-802.
6. McGeer PL, Itagaki S, Akiyama H, et al. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24 (4): 574-6.
7. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exper Neurol 2007; 208 (1): 1-25.
8. Nakamura Y. Regulating factors for microglial activation. Biol Pharma Bull 2002; 25 (8): 945-53.
9. Rezai-Zadeh K, Gate D, Town T. CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol 2009; 4 (4): 462-75.
10. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004; 10 (Suppl 1): S3-7.
11. Witte ME, Geurts JJ, de Vries HE, et al. Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 2010; 10 (5): 411-8.
12. Castaño A, Herrera AJ, Cano J, et al. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 1998; 70 (4): 1584-92.
13. De Pablos RM, Herrera AJ, Villarán RF, et al. Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB J: Official Publ Federat Am Soc Exp Biol 2005; 19 (3): 407-9.
14. Zecca L, Stroppolo A, Gatti A, et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 2004; 101 (26): 9843-8.
15. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996; 47 (6 Suppl 3): S161-70.
16. Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med Soc Exp Biol Med (New York, NY) 1999; 222 (3): 236-45.
17. Olanow CW. The pathogenesis of cell death in Parkinson's disease-2007. Mov Disord 2007; 22 (Suppl 17): S335-42.
18. Qin L, Wu X, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007; 55 (5): 453-62.
19. McCoy MK, Martinez TN, Ruhn KA, et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 2006; 26 (37): 9365-75.
20. Lee J-K, Tran T, Tansey MG. Neuroinflammation in Parkinson's Disease. J Neuroimmune Pharmacol 2009; 4 (4): 419-29.
21. Purisai MG, McCormack AL, Cumine S, et al. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis 2007; 25 (2): 392-400.
22. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006; 21 (2): 404-12.
23. Griffin WST, Liu L, Li Y, et al. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammat 2006; 3: 5.
24. Su X, Maguire-Zeiss KA, Giuliano R, et al. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 2008; 29 (11): 1690-701.
25. Klegeris A, Pelech S, Giasson BI, et al. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging 2008; 29 (5): 739-52.
26. Austin SA, Floden AM, Murphy EJ, et al. Alpha-synuclein expression modulates microglial activation phenotype. J Neurosci: official J Soci Neurosci 2006; 26 (41): 10558-63.
27. Tanaka S, Ishii A, Ohtaki H, et al. Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL-1 knockout mice. J Neuroinflammation. 2013; 10: 143.
28. Lindqvist D, Kaufman E, Brundin L, et al. Non-motor symptoms in patients with Parkinson's disease-correlations with inflammatory cytokines in serum. PloS one. 2012; 7 (10): e47387.
29. Zecca L, Wilms H, Geick S, et al. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta neuropathologica. 2008; 116 (1): 47-55.
30. Shamoto-Nagai M, Maruyama W, Yi H, et al. Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J Neural Trans 2006; 113 (5): 633-44.
31. Faucheux BA, Martin M-E, Beaumont C, et al. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 2003; 86 (5): 1142-8.
32. Shoham S, Youdim MB. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell Mol Biol 2000; 46 (4): 743-60.
33. McGeer EG, Singh EA, McGeer PL. Peripheral-type benzodiazepine binding in Alzheimer disease. Alzheimer Dis Assoc Disord 1988; 2 (4): 331-6.
34. Brochard V, Combadiere B, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119 (1): 182-92.
35. Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119 (1): 182-92.
36. Reynolds AD, Stone DK, Mosley RL, et al. Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol 2009; 182 (7): 4137-49.
37. Reynolds AD, Stone DK, Hutter JA, et al. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol (Baltimore, Md: 1950). 2010; 184 (5): 2261-71.
38. Stone DK, Reynolds AD, Mosley RL, et al. Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signaling 2009; 11 (9): 2151-66.
39. Reynolds AD, Banerjee R, Liu J, et al. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukocyte Biol 2007; 82 (5): 1083-94.
40. Gregori S, Casorati M, Amuchastegui S, et al. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol (Baltimore, Md: 1950). 2001; 167 (4): 1945-53.
41. Johnston LC, Su X, Maguire-Zeiss K, et al. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol Ther: J Am Soc Gene Ther 2008; 16 (8): 1392-9.
42. Schwartz M, Butovsky O, Brück W, et al. Microglial phenotype: is the commitment reversible? Trends Neurosci 2006; 29 (2): 68-74.
43. Hisanaga K, Asagi M, Itoyama Y, et al. Increase in peripheral CD4 bright +CD8 dull+ T cells in Parkinson disease. Arch Neurol 2001; 58 (10): 1580-3.
44. Baba Y, Kuroiwa A, Uitti RJ, et al. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 2005; 11 (8): 493-8.
45. Teismann P, Schulz JB. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 2004; 318 (1): 149-61.
46. Kortekaas R, Leenders KL, van Oostrom JCH, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005; 57 (2): 176-9.
47. Carvey PM, Zhao CH, Hendey B, et al. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci 2005; 22 (5): 1158-68.
48. Batchelor PE, Porritt MJ, Martinello P, et al. Macrophages and Microglia Produce Local Trophic Gradients That Stimulate Axonal Sprouting Toward but Not beyond the Wound Edge. Mol Cell Neurosci 2002; 21 (3): 436-53.
49. Iravani MM, Sadeghian M, Leung CC, et al. Lipopolysaccharide-induced nigral inflammation leads to increased IL-1beta tissue content and expression of astrocytic glial cell line-derived neurotrophic factor. Neurosci Lett 2012; 510 (2): 138-42.
50. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9 (5): 589-95.
51. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59 (3): 459-66.
52. Ossola B, Schendzielorz N, Chen SH, et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology 2011; 61 (4): 574-82.
53. Gao H-M, Kotzbauer PT, Uryu K, et al. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci: official J Soc Neurosci 2008; 28 (30): 7687-98.
54. Shimura H, Hattori N, Kubo Si, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25 (3): 302-5.
55. Tran TA, Nguyen AD, Chang J, et al. Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PloS one. 2011; 6 (8): e23660.
56. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011; 91 (4): 1161-218.
57. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005; 365 (9457): 410-2.
58. Gaig C, Ezquerra M, Marti MJ, et al. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 2006; 63 (3): 377-82.
59. Hakimi M, Selvanantham T, Swinton E, et al. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Trans 2011; 118 (5): 795-808.
60. Liu Z, Lee J, Krummey S, et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 2011; 12 (11): 1063-70.
61. Monticelli S, Rao A. NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription. Eur J Immunol 2002; 32 (10): 2971-8.
62. Reinhardt P, Schmid B, Burbulla LF, et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013; 12 (3): 354-67.
63. Botta-Orfila T, Morato X, Compta Y, et al. Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease. J Neurosci Res 2014; 92 (8): 1071-7.
64. Saijo K, Winner B, Carson CT, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009; 137 (1): 47-59.
65. Le W-D, Xu P, Jankovic J, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 2003; 33 (1): 85-9.
66. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 2010; 42 (9): 781-5.
67. Simon-Sanchez J, van Hilten JJ, van de Warrenburg B, et al. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Human Genet: EJHG 2011; 19 (6): 655-61.
68. Puschmann A, Verbeeck C, Heckman MG, et al. Human leukocyte antigen variation and Parkinson's disease. Parkinsonism Related Disord 2011; 17 (5): 376-8.
69. Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011; 377 (9766): 641-9.
70. Saiki M, Baker A, Williams-Gray CH, et al. Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. J Neurol, Neurosurg, Psych 2010; 81 (8): 890-1.
71. Mosley RL, Hutter-Saunders JA, Stone DK, et al. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2 (1): a009381.
72. Liberatore GT, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999; 5 (12): 1403-9.
73. Wu D-C, Teismann P, Tieu K, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 2003; 100 (10): 6145-50.
74. Gao HM, Zhang F, Zhou H, et al. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect 2011; 119 (6): 807-14.
75. Ghosh A, Roy A, Liu X, et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2007; 104 (47): 18754-9.
76. Teismann P, Vila M, Choi DK, et al. COX-2 and neurodegeneration in Parkinson's disease. Ann New York Acad Sci 2003; 991: 272-7.
77. Sánchez-Pernaute R, Ferree A, Cooper O, et al. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 2004; 1 (1): 6.
78. Thakur P, Nehru B. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease. Neuroscience 2013; 231: 420-31.
79. Tasaki Y, Yamamoto J, Omura T, et al. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model. Neurosci Lett 2012; 521 (1): 15-9.
80. Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005; 58 (6): 963-7.
81. Chen H, Zhang SM, Hernán MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60 (8): 1059-64.
82. Becker C, Jick SS, Meier CR. NSAID use and risk of Parkinson disease: a population-based case-control study. Eur J Neurol: official J Eur Federat Neurol Soc 2011; 18 (11): 1336-42.
83. Driver JA, Logroscino G, Lu L, et al. Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study. BMJ (Clin Res ed). 2011;342:d198.
84. Hernán MA, Logroscino G, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006; 66 (7): 1097-9.
85. Samii A, Etminan M, Wiens MO, et al. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009; 26 (9): 769-79.
86. Rees K, Stowe R, Patel S, et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane database Syst Rev 2011 (11): Cd008454.